GLP-1受容体の細胞外表面はバイアスアゴニズムの分子トリガーである
Denise Wootten1, Christopher A Reynolds2, Kevin J Smith2
1Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
Cell
|June 18, 2016
まとめ
Gタンパク質結合受容体 (GPCRs) のリガンド誘導信号バイアスは,より安全な治療法として活用できます. リガンド結合が受容体活性化とバイアスシグナル伝達をどのように開始するかを理解することは,薬剤設計の鍵です.
科学分野:
- 薬理学について
- 生物化学
- 構造生物学
背景:
- Gタンパク質結合受容体 (GPCR) のリガンド誘導信号バイアスは,選択的に細胞応答を調節することによって,より安全な治療法を開発するための有望な道を示しています.
- リガンド結合と細胞内シグナル伝達を結びつける分子メカニズムを理解することは,シグナルバイアスを効果的に利用するために極めて重要です.
- クラスBのGPCRの活性化には,ペプチドのN端と受容体核の相互作用が含まれる.
研究 の 目的:
- クラスBのGPCRにおける細胞内シグナル伝達へのリガンド結合の分子現象を解明する.
- 受容体改変の機能的結果を受容体-リガンド複合体の3次元モデルにマッピングする.
- 受容体活性化開始とバイアスアゴニズムのメカニズム的基礎に関する分子洞察を提供する.
主な方法:
- 経路特異的なシグナリング効果とアゴニストの afinity の修正を区別するために,高度な分析技術を使用した.
- レセプター-リガンド複合体の3Dモデルにレセプター改変の機能的影響をマッピングした.
- 受容体活性化とバイアスアゴニズムメカニズムの開始を調査した.
主要な成果:
- ペプチドアゴニストは,受容体の細胞外面の異なる領域と相互作用して,特定のエフェクタカップリングとバイアス信号を誘発することができる.
- 先進的な分析方法により,経路特異のシグナル伝達とアゴニストの親和性変化の影響を成功裏に分離した.
- 受容体改変の機能的影響は3D受容体-リガンド複合体モデルにマッピングされた.
結論:
- この研究は,GPCR活性化の開始とバイアスアゴニズムのメカニズム的基礎に関する分子洞察を提供します.
- 異なるペプチドアゴニストと受容体の細胞外面の相互作用により,異なるエフェクタ結合とバイアスシグナル伝達が生じる.
- 治療用バイアスアゴニストの合理的な設計のための基礎を築いた.
関連する概念動画
01:24Glucagon-like Receptor Agonists
1.2K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
01:09GPCRs Regulate Adenylyl Cylase Activity
8.2K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.2K
01:30Transducer Mechanism: G Protein–Coupled Receptors
7.2K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
7.2K
01:12GPCR Desensitization
8.6K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
8.6K
01:30Spare Receptors
4.8K
Some receptors remain unoccupied even when an agonist produces a maximal response. Such empty ones are called spare receptors. In presence of spare receptors the maximum effect of an agonist drug is achieved with fewer than 100% of the receptors being occupied. To determine the presence of spare receptors, scientists often compare the concentration of the drug needed to produce 50% of the maximum effect (EC50) with the concentration of the drug needed to occupy 50% of the receptors (Kd). If the...
4.8K
01:29The Two-State Receptor Model
3.4K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
3.4K